Coherus Biosciences Inc [NASDAQ: CHRS] plunged by -$0.03 during the normal trading session on while it closed the day at $0.97.
Coherus Biosciences Inc stock has also loss -6.67% of its value over the past 7 days. However, CHRS stock has declined by -41.53% in the 3 months of the year. Over the past six months meanwhile, it has lost -59.73% and lost -70.85% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for CHRS stock reached $111.82 million, with 112.22 million shares outstanding and 110.58 million shares in the current float. Compared to the average trading volume of 2.15M shares, CHRS reached a trading volume of 3074219 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Coherus Biosciences Inc [CHRS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CHRS shares is $7.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CHRS stock is a recommendation set at 1.75. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Coherus Biosciences Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 16, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on November 17, 2023, representing the official price target for Coherus Biosciences Inc stock.
The Average True Range (ATR) for Coherus Biosciences Inc is set at 0.10, with the Price to Sales ratio for CHRS stock in the period of the last 12 months amounting to 0.36.
CHRS stock trade performance evaluation
Coherus Biosciences Inc [CHRS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.67. With this latest performance, CHRS shares dropped by -27.02% in over the last four-week period, additionally sinking by -59.73% over the last 6 months – not to mention a drop of -74.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CHRS stock in for the last two-week period is set at 35.73, with the RSI for the last a single of trading hit 32.43, and the three-weeks RSI is set at 37.90 for Coherus Biosciences Inc [CHRS]. The present Moving Average for the last 50 days of trading for this stock 1.2307, while it was recorded at 1.0241 for the last single week of trading, and 1.9215 for the last 200 days.
Coherus Biosciences Inc [CHRS]: An insightful look at the core fundamentals
Coherus Biosciences Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.07 and a Current Ratio set at 1.21.
Earnings per share (EPS) analysis for Coherus Biosciences Inc [CHRS] stock
With the latest financial reports released by the company, Coherus Biosciences Inc posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CHRS.
Coherus Biosciences Inc [CHRS]: Institutional Ownership
There are presently around $73.30%, or 74.33%% of CHRS stock, in the hands of institutional investors. The top three institutional holders of CHRS stocks are: BLACKROCK INC. with ownership of 11.75 million shares, which is approximately 10.4236%. VANGUARD GROUP INC, holding 10.6 million shares of the stock with an approximate value of $$18.34 million in CHRS stocks shares; and VANGUARD GROUP INC, currently with $$17.99 million in CHRS stock with ownership which is approximately 9.224%.
